$VMD

VieMed Healthcare (VMD) reported less than 10% market penetration in its noninvasive ventilation service, with 25M U.S. COPD patients and 60K Medicare beneficiaries using its services. The company expanded into sleep, oxygen, and maternal health, with sleep therapy revenue up 44% YoY. VieMed completed three acquisitions, expects $317M revenue in 2026, and has no net debt. Management projects adjusted EBITDA of $66M and share repurchases.

VMD Corp, part of Xcelerate Solutions, won a spot on the TSA's SPP IDIQ contract, valued up to $5bn. This positions the company to bid on future aviation security projects. VMD already supports screening at airports like Kansas City and San Francisco.

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

VieMed Healthcare reported 2025 results with $270.3M revenue, $61.4M Adjusted EBITDA, and $28.1M free cash flow. For 2026, it projects $314M–$320M revenue and $64M–$68M Adjusted EBITDA, with a new share buyback program. The company highlights growth, cash generation, and strategic initiatives.

Viemed Healthcare (VMD) director Randy E. Dobbs settled 16,763 Restricted Stock Units and 4,191 Phantom Share Units, acquiring and then disposing of 4,191 common shares at $8.94 each. He also received a new grant of 16,848 RSUs, vesting in 2027. The transactions reflect insider equity award activity.

Viemed Healthcare (VMD) director Sabrina Heltz exercised 15,029 RSUs and 3,757 Phantom Share Units, converting them into common shares. She also received new grants of 12,174 RSUs and 3,043 Phantom Share Units, set to vest in 2027. The Phantom Share Units were settled at $8.94 per share.

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 results for the three and six months ended June 30, 2026 and updated 2026 guidance. Cash was $10.7M, working capital $6.1M, and it repaid $2.2M of a term loan. Net revenue guidance was raised at the low end; net capex is now 8.5% to 10.0% of net revenue.